CLINICAL TRIALS PROFILE FOR VOLIXIBAT
✉ Email this page to a colleague
Clinical Trials for Volixibat
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02475317 ↗ | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion | Completed | Mirum Pharmaceuticals, Inc. | Phase 1 | The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same. |
| NCT02475317 ↗ | Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion | Completed | Shire | Phase 1 | The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same. |
| NCT02787304 ↗ | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) | Terminated | Mirum Pharmaceuticals, Inc. | Phase 2 | The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH). |
| NCT02787304 ↗ | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) | Terminated | Shire | Phase 2 | The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH). |
| NCT04663308 ↗ | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | Recruiting | Mirum Pharmaceuticals, Inc. | Phase 2 | The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC. |
| NCT04718961 ↗ | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) | Recruiting | Mirum Pharmaceuticals, Inc. | Phase 2 | The purpose of this clinical research study is to evaluate the efficacy, safety and tolerability of the study medicine, volixibat, in patients with Intrahepatic cholestasis of pregnancy (ICP) and elevated serum bile acid concentrations. |
| NCT05050136 ↗ | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Recruiting | Mirum Pharmaceuticals, Inc. | Phase 2 | The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Volixibat
Condition Name
Clinical Trial Locations for Volixibat
Trials by Country
Clinical Trial Progress for Volixibat
Clinical Trial Phase
Clinical Trial Sponsors for Volixibat
Sponsor Name
